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ABSTRACT 
Over the past 40 years various behavioral techniques and pharmaceutical adjuncts have 
been developed to aid in smoking cessation.  The continued need for the development of 
new and more effective pharmaceutical adjuncts for smoking cessation is evident by the 
large number of individuals continuing to smoke despite their knowledge of the 
significant health risks associated with tobacco use.  Bupropion recently has been found 
to be a useful pharmaceutical agent in furthering smoking abstinence, but the long-term 
effectiveness of the drug is mediocre at best.  In order to gain a better understanding of 
how bupropion affects smoking, the current studies investigated the effects of bupropion 
in a rodent model of nicotine self-administration.  In the nicotine study, subjects self-
administered nicotine (0.03 mg/kg/inf) under a fixed-ratio 3 (FR3) 60 s timeout (TO) 
schedule of reinforcement.  The effects of bupropion on food-maintained responding 
using two levels of food deprivation (food-deprived and food-satiated) were used to 
assess the specificity of the effects of the drug on nicotine self-administration.  Once 
subjects acquired stable rates of responding, they were pretreated 15 min prior to 60 min 
sessions with various doses of bupropion (0, 10, 30, 56 mg/kg, IP).  The 30 mg/kg dose 
of bupropion resulted in an increase in nicotine intake while the drug dose-dependently 
decreased food-maintained behavior under deprivation conditions.  When more 
comparable rates of behavior in the food-satiated group were investigated, bupropion had 
similar effects on nicotine and food-maintained responding.  The current studies indicate 
that response rate must be considered when evaluating selective effects of drugs.  The 
findings that bupropion can increase moderate rates of nicotine self-administration at 
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doses that decrease higher rates of responding maintained by food suggest that adding 
alternative reinforcers to the environment of individuals attempting to quit could affect 
the drug’s ability to sustain abstinence. 
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INTRODUCTION 
 
Nicotine is a natural, pharmacologically active alkaloid compound, found in the 
tobacco plant.  Although nicotine is only one of approximately 4,000 chemicals found in 
the smoke from tobacco products, it has been determined to be the major component 
responsible for maintaining human smoking (Stolerman & Jarvis, 1995).  The first 
reported use of smoked tobacco dates back to the late 15th century when European 
explorers discovered Native Americans smoking tobacco leaves.  The use of tobacco 
products grew rapidly across North America and Europe.  With the development of more 
efficient manufacturing techniques in the late 19th century, use of tobacco products in the 
early 20th century skyrocketed.  Tobacco use increased in the twentieth century until use 
declined around 1964 following the surgeon general’s report linking tobacco use to 
various illnesses.  
Although the detrimental effects of smoking have been known for over 30 years, 
the rate of tobacco use in the United States continues to be extensive with an estimated 57 
million Americans using cigarettes and an additional 7.6 million individuals using 
smokeless tobacco products (National Institute on Drug Abuse, 2000).  The amount of 
tobacco use worldwide is even more striking, with an estimated one billion smokers 
currently in the world (Vainio, Weiderpass, & Kleihues, 2001).  Such wide spread use of 
tobacco products results in detrimental health consequences to the world’s population.  
Nearly 430,000 Americans die each year due to tobacco-related diseases.  The World 
Health Organization predicts that health-care problems associated with tobacco use will 
be the leading health concern by the year 2020 and is currently associated with nearly 8.4 
million deaths per year worldwide (Vainio et al.).  The exact cause of death associated 
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with tobacco use varies depending on the geographical area.  In the United States, the 
leading causes of smoking-related death are lung cancer and vascular diseases (Vainio et 
al.).   
Most of the adverse heath effects of tobacco products are not directly related to 
nicotine but rather to the estimated 50 carcinogens contained in cigarette smoke (Shields, 
2000).  Two of the most potent carcinogens are tobacco-specific nitrosamines (TSN), 
which results from the curing process of the tobacco leaf, and polycyclic aromatic 
hydrocarbons (PAHs), which results from incomplete burning of the tobacco leaf.  Both 
carcinogens result in DNA damage that increases the likelihood of lung and other types 
of cancers (Shields).   There are several factors that affect the amount of exposure to 
these carcinogens: length of inhalation, number of cigarettes smoked, puff volume, and 
number of puffs per cigarette (Shields).  An interesting note is that in recent years 
tobacco manufacturers have decreased the amount of tar and nicotine the individual is 
exposed to in cigarettes in order to market a safer cigarette.  The companies may have 
inadvertently achieved the opposite effect, because humans will self-titrate their levels of 
nicotine by increasing the number of cigarettes smoked, puff duration, and length of 
inhalation, in effect putting themselves at greater risk for carcinogens (Shields). 
With the adverse health effects widely known, there has been a decline in 
smoking rates in the United States since the 1960 s (Fiore et al., 1990).   Although 70% 
of current smokers say they want to quit smoking, only 46% of these smokers attempt to 
quit each year (NOP Omnibus Services, 1992), and only 10% of the individuals who 
attempt to quit succeed (Fiore et al.).  The difficulty in smoking cessation is illustrated by 
the fact that 97% of smokers who attempt to quit smoking without treatment relapse 
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within the first 6 months of cessation (Hughes, 1992).  The benefits that can result from 
smoking cessation are substantial; quitting smoking greatly reduces the likelihood of 
developing lung cancer when compared to individuals who continue to smoke (Peto et 
al., 2000).   Individuals who stop smoking at around 30 years of age can evade more than 
90% of the health risks attributed to tobacco use (2000); by avoiding these health risks a 
considerable number of future deaths associated with tobacco use can be averted or 
eliminated. 
The most common use of tobacco products in the United States is cigarette 
smoking.  Smoking allows for nicotine to be delivered rapidly to the lungs of the 
individual.  Nicotine is taken into the lungs as tiny particles or tars, which are suspended 
in the tobacco smoke.  Once into the lungs, nicotine binds to hemoglobin and is then 
transported throughout the body.  Nicotine acts on the nicotinic acetylcholine receptors 
(nAChRs) that are located in both the peripheral and central nervous system. In the 
peripheral nervous system the effects of nicotine are due to the activation of nAChRs on 
ganglion cells and the neuromuscular junctions of the skeletal muscles, where it 
stimulates the release of acetylcholine.  In the central nervous system there are two major 
cholenerigic projections: one originates in the tegmentum with terminal fields in the 
thalamus and midbrain, and the second major cholenerigic projection starts in the basal 
forebrain and projects to the hippocampus and throughout the cortex (Dani, 2001).  
Nicotinic receptors that appear to be responsible for the compulsive and chronic use of 
tobacco products by humans are located primarily in one area of the brain, the 
mesolimbic dopamine pathway (Balfour, 1994; Corrigall, Franklin, Coen, & Clarke, 
1992; Dani & Heinemann, 1996).  The mesolimbic dopamine pathway originates in the 
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Ventral Tegmental Area with neural projections to the nucleus accumbens and to the 
prefrontal cortex.  Nicotine’s activation of this pathway results from the binding of 
nicotine to nAChRs found on the cell bodies of neurons in the ventral tegmental area and 
on their terminal regions in the nucleus accumbens (Calabresi, Lacey, & North, 1989; 
Corrigall, Coen, & Adamson, 1994).   The binding of nicotine to these receptors results in 
an increase in the levels of extracellular dopamine in the nucleus accumbens, a property it 
shares with other drugs of abuse such as amphetamine, cocaine, alcohol, and opiates 
(Pontieri, Tanda, Orzi, & Di Chiara, 1996).      
Nicotinic acetylcholine receptors in the central nervous system and peripheral 
nervous system are ligand-gated receptors that are composed of different combination of 
α, β, γ, δ, and ε proteins or subunits (Itier & Bertrand, 2001).  Once a neurotransmitter 
binds to the appropriate protein of a ligand-gated receptor, the signal is transmitted by a 
change in the conformation of the channel, which alters the flow of ions into the neuron.  
The different subunits combine in various ways to create functionally different receptors.  
A receptor composed of a particular set of subunits may have a higher affinity for 
acetylcholine than a receptor composed of a different set of proteins.  For example, 
nAChRs with the α7 subunit have a high permeability for calcium and have a rapid 
activation and desensitization.  Receptor agonists can facilitate the activation of 
receptors; antagonists can block the activation of receptors.  Drugs such as nicotine and 
black widow spider venom function as nicotinic agonists.  Mecamylamine, 
chlorisondamine, and Dihydro-β-erythroidine (DHβE) are drugs that function as central 
nicotinic antagonists.   Researchers have found that the β2 subunit is one of the subunits 
found to be important in the reinforcing effects of nicotine (Picciotto et al., 1998).  This is 
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evident from the Picciotto et al. study where mice that lacked the gene which encodes for 
the β2  subunit showed marked decrease in the levels of self-administered nicotine 
compared to mice that did not lack the β2 subunit.  The β2 subunit was specific to nicotine 
self-administration in that mice which lacked the β2 subunit did acquire cocaine self-
administration (Picciotto et al.).    
In order to gain a better understanding of how nicotine and other drugs lead to 
addiction, researchers have developed laboratory models of drug abuse.  Researchers 
often bring subjects into a laboratory setting where the environment and dosing of the 
drug can be controlled.  In early human laboratory self-administration studies involving 
nicotine, acute pretreatment with mecamylamine caused an increase in the rate of 
cigarette smoking in chronic smokers (Stolerman, Goldfarb, Fink, & Jarvik, 1973).  The 
increase in rate of smoking was suggested to be a compensatory response to the effects of 
mecamylamine resulting from the subjects self-triturating the level of nicotine in their 
body (Pomerleau, Pomerleau, & Majchrzak, 1987).  This effect of nicotinic antagonists 
increasing the rate of cigarette smoking is comparable to the increase in cigarette 
smoking seen by individuals that smoke cigarettes with less nicotine.   
Researchers have also developed animal models of human drug abuse that result 
in even more experimental control within a study.  The animal self-administration model 
has been widely accepted as a valid means to study the abuse liability of drugs (Schuster 
& Thompson, 1969).  One way to judge the abuse potential of drugs is to determine 
whether the drug will be self-administrated, or function as a reinforcer in an animal self-
administration paradigm (Schuster & Thompson, 1969).  A reinforcer is an event that 
increases the probability of the behavior that produced it.  In self-administration studies, a 
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subject is placed into an experimental chamber in which some behavior (often a lever 
press) must be performed to gain access to a drug.  If the required behavior increases in 
frequency, compared to alternative behaviors (e.g. grooming), then the drug maybe acting 
as a positive reinforcer and may have abuse potential in humans (Schuster & Thompson, 
1969). 
In early animal self-administration studies involving nicotine, monkeys were 
placed into an experimental chamber and allowed to suck on a tube that resulted in the 
delivery of cigarette smoke (Ando & Yanagita, 1981; Glick, Canfield, & Jarvik, 1970; 
Glick, Jarvik, & Nakamura, 1970; Yanagita, Ando, Kato, & Takada, 1983).  The subjects 
were given a choice between a tube that resulted in cigarette smoke and an alternative 
tube that resulted in the delivery of air (Glick, Canfield et al., 1970; Glick, Jarvik et al., 
1970).  These studies found that a majority of monkeys chose smoke over air and 
persisted to choose smoke over air under a concurrent choice schedule of reinforcement.  
When the subjects were administered mecamylamine, the subjects switched their 
behavior to the tube that supplied only air.  These results offered some evidence that 
nicotine was maintaining smoking (Glick, Jarvik et al.).  As mentioned above, the 
Stolerman et al. (1973) study demonstrated that administration of mecamylamine to 
humans resulted in an increase in smoking while the Glick, Jarvik et al, study reported a 
decrease in non-human primates.  The difference in the effects of mecamylamine 
between the non-human primate and human studies can most likely be attributed to the 
differences in the length of mecamylamine treatment and the subjects’ differences in 
smoking history (Stolerman et al.).  For instance, in the Glick, Jarvik et al. study monkeys 
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were repeatedly administered mecamylamine, while human subjects in the Stolerman et 
al. study received only a single dose of the drug.  
Inhalation is not the only route of administration that is used in animal models of 
drug self-administration.  An intravenous route of self-administration is more often used 
in animal studies.  This route involves surgically implanting a catheter into a vein, often 
the jugular vein, of the animal, which allows the drug to be delivered directly to the heart.  
Investigations using the intravenous route of administration have increased the generality 
of the conditions under which nicotine functions as a reinforcer.   
The first study to demonstrate that intravenous infusions of nicotine could 
function as reinforcers was reported by Goldberg, Spealman, and Goldberg (1981) using 
a second-order schedule of reinforcement with squirrel monkeys.  A second-order 
schedule consists of two or more simple schedules where behavior under one schedule is 
reinforced under another schedule.  Two schedules that are often used in a second-order 
schedule are fixed-interval (FI) and fixed-ratio (FR) schedules.  Under an FI schedule of 
reinforcement, the first response by a subject following a fixed amount of time results in 
the delivery of a reinforcer.  An FR schedule of reinforcement requires the subject to emit 
a set or fixed number of responses before a reinforcer is delivered.  For example, in a 
second-order schedule of FI 2 min(FR 10:Sp) every tenth response results in the brief 
onset of some sort of stimulus, the first FR 10 completed after the FI 2 min elapses 
resulted in the delivery of a reinforcer and the onset of the stimulus.  This schedule is 
often used because the experimenter can control the temporal spacing of infusions, and it 
produces a stable rate of responding (Swedberg, Henningfield, & Goldberg, 1990).  In the 
Goldberg et al. (1981) study, a second-order schedule of FI 2 min(FR 10:Sp) was used. 
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The stimulus lights flashed after every tenth response and the stimulus light came on 
during the delivery of the reinforcer, which was an infusion of nicotine (0.03 mg/kg).  
When the stimulus lights were removed, the rate at which the subjects responded 
decreased; when the stimulus lights were reinstated, the rate of behavior returned to the 
original baseline rate of responding (Goldberg et al., 1981).  This experiment revealed 
that nicotine could act as a reinforcer under a second-order schedule and that 
environmental cues associated with nicotine delivery are important in the persistence of 
drug-seeking behavior (Goldberg et al., 1981).  These results were the first to indicate 
that intravenous injections of nicotine could maintain high and persistent rates of 
responding since a previous study had found that nicotine would not maintain responding 
in baboons (Griffiths, Brady, & Bradford, 1979).  
The generality of the hypothesis that nicotine functions as a reinforcer was further 
increased when it was found that humans (Henningfield & Goldberg, 1983) and rats 
(Corrigall & Coen, 1989) would self-administer intravenous injections of nicotine.  In the 
procedure developed by Corrigall and Coen, the experimental session was limited to one 
hour, using a FR 5 schedule of nicotine infusion.  Each nicotine infusion was followed by 
a 1 min signaled timeout (TO); during the TO periods no further reinforcers could be 
delivered.  By limiting the number of infusions delivered within a session and the rate at 
which the infusions can be obtained, the subjects could self-administer nicotine without 
being exposed to toxic levels.  In the Corrigall and Coen study, the animals were first 
trained to respond using food as the reinforcer; then the animals were implanted with a 
jugular catheter.  Following recovery from surgery, animals were exposed to 
experimental sessions in which food was replaced with nicotine infusions.  Using this 
 9  
    
procedure Corrigall and Coen found that nicotine could act as a reinforcer in rats under 
limited-access conditions and that pre-treatment with mecamylamine (a nicotinic 
antagonist) decreased nicotine self-administration.  These findings were replicated by 
Donny, Caggiula, Knopf, and Brown (1995), providing additional support that 
intravenous infusions of nicotine under a limited-access schedule could function as a 
reinforcer. 
The Donny et al. (1995) study also determined that the conditions under which 
nicotine will maintain responding appear to be much restricted than with other drugs of 
abuse.  Under schedule contingencies different than Corrigall and Coen (1989) and 
Goldberg et al. (1981), nicotine has been shown to suppress responding (Goldberg & 
Spealman, 1983), or to maintain responding that postpones its programmed infusion 
(Spealman, 1983).  A study involving a schedule similar to the limited-access schedule 
used by Corrigall and Coen found that nicotine would not maintain consistent responding 
(Dworkin, Vrana, Broadbent, & Robinson, 1993).   Despite the fact that Dworkin et al. 
did not show nicotine self-administration under a standard FR schedule, the study did 
report that nicotine self-administration might be dependent on the level of food 
deprivation under more complex schedules.  Dworkin et al. found that when rats were 
placed under concurrent schedules of nicotine, food, and water presentation, and 
underwent extinction in the food schedule, nicotine self-administration increased.  
Extinction of the water component did not result in an increase in nicotine self-
administration.  The importance of food deprivation is noted in other studies with 
nicotine (Corrigall & Coen, 1989; Donny et al., 1995; Donny et al., 1998) and is 
congruent with experiments that demonstrate increases in levels of food deprivation 
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result in increases in self-administration of several different drugs (e.g. Carroll & Meisch, 
1981, 1984). 
 Another important variable that appears to have an effect on nicotine self-
administration is the genetic strain of the rodent that is used (Shoaib, Schindler, & 
Goldberg, 1997).  These results may account for the Dworkin et al. (1993) study’s 
inability to show consistent nicotine self-administration.  Also, the speed of the infusion 
of nicotine was found to be an important variable in maintaining nicotine self-
administration in a study by Valentine, Hokanson, Matta, and Sharp (1997) using an 
unlimited access schedule.  Valentine et al. (1997) found that as the injection time 
increased from 2-3 seconds the reinforcing efficacy of nicotine, or it’s ability to maintain 
responding, decreased. 
 With the development and refinement of experimental paradigms which assess 
the reinforcing effects of nicotine research was quickly undertaken to determine the 
neural mechanisms associated with nicotine self-administration.  Corrigall, Franklin, 
Coen, and Clark (1992) demonstrated that the administration of nicotine resulted from the 
drug’s effects on the central nervous system by assessing the effects of injecting 
chlorisondamine (a long-lasting nicotinic antagonist) into the brain. Central 
administration of chlorisondamine resulted in a decrease in nicotine self-administration 
(Corrigall et al., 1992).  It was found that lesions to the mesolimbic dopamine pathway 
produced by infusion of 6-hydroxydopamine into the nucleus accumbens (NA) resulted 
in decreases in nicotine self-administration (Corrigall et al., 1992).  The lesions to the 
mesolimbic dopamine pathway resulted in a decrease in the amount of dopamine in the 
terminal field of the mesolimbic dopamine pathway in the NA (Corrigall et al., 1992).  
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The mechanism by which nicotine increases levels of extracellular dopamine in the NA 
was clarified when it was found that infusions of the nicotinic antagonist DHβE into the 
ventral tegmental area (VTA) produced a significant decrease in nicotine self-
administration (Corrigall et al., 1994).  The decrease in responding following the delivery 
of the nicotinic antagonist was specific to nicotine self-administration in that infusions of 
DHβE into the VTA had no effect on cocaine self-administration or food-maintained 
responding (Corrigall et al., 1994).  As mentioned earlier, molecular genetic research also 
has made use of the self-administration paradigm when investigating which nicotinic 
receptor subtypes (β2) are involved in nicotine self-administration (Picciotto et al., 1998).   
Animal self-administration studies have allowed for a better understanding of 
three important components of substance abuse: acquisition, maintenance, and 
reinstatement or relapse (Dworkin & Stairs, 2002).  This better understanding of drug 
abuse can aid in the development of potential pharmacotherapeutic treatments for drug 
addiction as well as for smoking cessation.  When developing pharmacotherapeutics it is 
important to determine whether the compound has reinforcer-specific effects.  One 
procedure often used to test the specificity of the drug is to determine the effect of the 
drug on food-maintained responding (Mello, 1992).  If a novel compound was found to 
decrease nicotine self-administration with little to no effect on behavior maintained by 
food, this would indicate that the drug’s effects on nicotine self-administration were 
selective.   
In addition to reinforcer selectivity, there are additional concepts to consider when 
investigating the effects of drugs on schedule-controlled behavior.  One very important 
concept that must be considered is rate dependency.  Rate dependency is the notion that, 
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the rate of the ongoing behavior at the time the drug is administered may influence the 
effect of the compound on responding.  It is widely known in behavioral pharmacology 
research that stimulants tend to decrease high rates of behavior and increase low rates of 
behavior that are maintained through positive reinforcement (Dews, 1955, 1958; 
McMillan & Leander, 1976).  While many have described the effects of stimulants on 
schedule-controlled behavior in terms of rate dependency, others have described the data 
using the notion of rate constancy.  Rate constancy is the notion that administration of 
stimulants causes behavior to become more constant or less variable, and that as the dose 
of the drug is increased the behavior becomes less and less variable (Gonzalez & Byrd, 
1977).  Despite the description used to describe the effects of stimulants on the schedule-
controlled behavior, the consistent effects of stimulants on schedule-controlled behavior 
must be considered when using animal self-administration procedures as well as food 
control studies to test for potential pharmacotherapeutics.   
Some of the current pharmacotherapeutics available for smoking cessation 
include nicotine substitution therapy (Transdermal Nicotine Study Group, 1991) and the 
use of nicotinic antagonists (Rose, Behm, & Westman, 1998).  In addition, combination 
treatments have also been used involving both nicotine substitution and the blockade of 
nicotinic receptors (Rose, Behm, & Westman, 2001). The recent use of bupropion, an 
atypical anti-depressant, has likewise been found to be an effective aid in smoking 
cessation (Hurt et al., 1997; Jorenby et al., 1999).   
Nicotine substitution therapy involves replacing the nicotine usually acquired 
from cigarette smoke with nicotine from gum, patches, nasal spray, or a vapor delivery 
system (Transdermal Nicotine Study Group, 1991).  Individuals who use the nicotine 
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substitution therapy are 2-3 times more likely to remain abstinent then individuals who 
received placebo (Fiore, Smith, Jorenby, & Baker, 1994).  Although nicotine substitution 
therapy performs better than placebo in sustaining smoking abstinence, this therapy alone 
does not guarantee complete abstinence from smoking.   For instance, in a meta-analysis 
review of the clinical trials for the nicotine patch, it was found that the nicotine patch 
performed statistically better than placebo (Fiore et al.), but only 27% of the individuals 
who received the nicotine patch remained abstinent by the end of the treatment.  In 
addition, in the Gourlay et al. (1995) study, only 2.5% of individuals abstained 
continuously from smoking for 56 days after the quit date, compared to 2.2% for placebo.   
In an effort to improve the success rate of smoking cessation, other 
pharmaceuticals such as nicotinic antagonists have been investigated and compared to 
nicotine substitution.  These pharmacological adjuncts may be used alone or in 
combination with nicotine substitution therapy.  Recently, investigators testing the 
possibility of nicotinic antagonists to aid in smoking cessation have resulted in some 
success (Rose et al., 1998; Rose et al., 1994; Rose, Westman, Behm, Johnson, & 
Goldberg, 1999).  Rose et al. (1998) found that administering mecamylamine (a nicotinic 
antagonist) two weeks prior to the start of smoking cessation increased the duration of 
continuous abstinence when compared to nicotine substitution therapy alone.  The 
combination of mecamylamine and nicotine substitution delivered before the start of 
cessation increased rates of continuous abstinence higher than mecamylamine alone 
(Rose et al., 1998).  
Recently, a sustained release form of bupropion (Zyban, Glaxo Wellcome, Inc) 
has been approved for use in smoking cessation.  Bupropion is a psychostimulant that 
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acts primarily on the CNS and blocks the reuptake of monoamine neurotransmitters 
(Cooper, Hester, & Maxwell, 1980).  Recent evidence shows that bupropion may be a 
nicotinic antagonist (Slemmer, Martin, & Damaj, 2000).   The effectiveness of bupropion 
as an adjunct in smoking cessation was founded by two clinical studies that showed 
bupropion to perform better then placebo in furthering smoking cessation (Hurt et al., 
1997; Jorenby et al., 1999).  Hurt et al. found in a randomized, double blind study that the 
effect of bupropion was significant over placebo in increasing smoking cessation rates 
after six weeks.  The percentage of subjects not smoking at six weeks was dose 
dependent, with higher rates of abstinence occurring among subjects receiving the larger 
dose of sustained release bupropion.  Rates of abstinence continuously declined 
throughout the remaining year.  In a second randomized, double blind, placebo-controlled 
study investigating the effects of bupropion in combination with nicotine transdermal 
patches on smoking cessation, researchers found that 150 mg of bupropion with a 
nicotine patch had significant effects on smoking abstinence (Jorenby et al.).   Jorenby et 
al. found that at six months, bupropion alone produced higher rates of abstinence than did 
placebo or nicotine patch alone.  Bupropion in combination with the nicotine patch 
produced significantly higher rates of abstinence then bupropion alone or nicotine patch 
alone.  The results from these clinical trials appear promising, although rates of 
abstinence in both studies consistently declined with the passage of time, with only 
24.4% of the subjects receiving the highest dose of bupropion remaining abstinent at 12 
months.    
The effects of bupropion on smoking cessation may be better understood by the 
use of operant techniques in the animal self-administration design.  The effects of this 
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drug on nicotine-taking behavior as well as behavior maintained by food reinforcement 
under a similar schedule can shed light on how bupropion is having an effect on smoking 
cessation.  The current studies were undertaken to determine whether bupropion has 
reinforcer-specific effects on nicotine by testing the drug on nicotine self-administration 
and food-maintained behavior in rats. 
 
METHODS - NICOTINE EXPERIMENT 
 
Subjects 
 
Fifty male Sprague Dawley (from Harlan International) rats were used as subjects 
in this study, while seven subjects are shown in results section due to catheter failure or 
inability of nicotine to maintain responding.  The subjects were approximately two 
months old at the start of the experiment, and their weights during the experiment were 
approximately 300 g.  The subjects were individually housed in Plexiglas cages with 
cedar bedding.  The animals had unlimited access to water except during experimental 
sessions.  The subjects were fed 13-15 g of standard rat chow (LabDiet) following each 
daily session and were housed in reverse light-dark cycle (lights on from 19:00 to 07:00).     
Apparatus 
 Daily sessions were conducted in operant chambers inside sound-attenuating 
boxes (Med Associates).  Each sound-attenuating box contained an operant chamber, 
tone generator, white house light, pellet dispenser, ventilation fan, and an infusion pump 
(Med Associates, PHM-103).  The dimensions of the operant chambers were 22.86cm X 
21.59cm X 20.32cm.  The floor of the chambers consisted of metal bars spaced 1.27cm 
apart.  The two sidewalls and lid of the chambers were made of Plexiglas.  The front and 
back walls were constructed of aluminum.  On the front wall there was an active lever 
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that was 2.57cm above the floor and 2.57cm in from the right sidewall.  A minimum of 
approximately 0.25 N of force was required to operate the active lever. Centered 5.08cm 
above the active lever was a green-jeweled light.  A food cup was located 5.08cm from 
the left of the active lever and 2.57cm up from the floor.  On the back wall was an 
inactive lever that was 2.57cm from the left sidewall and 2.57cm above the floor. 
Centered 5.08cm above the inactive lever was a red-jeweled light.   
Surgery 
 Subjects were implanted with an indwelling jugular venous catheter.  The subjects 
were anesthetized with sodium pentobarbital (Nembutal, 40 mg/kg, i.p.), and injected 
with atropine sulfate (10 mg/kg) before the surgery.  The catheter, a small polyvinyl 
tubing, was inserted into the right facial vein.  The catheter was pushed down into the 
jugular vein, and rested just outside the right atrium of the heart.  The catheter was 
secured down and threaded subcutaneously out the back of the animal.  The catheter 
exited the subject through a polycarbonate back-plate that was implanted under the skin.  
The catheter was then passed through a spring leash and connected to a liquid swivel.  
The spring leash was connected to the back-plate of the animal by two nylon screws.  The 
swivel was then connected to a counterbalanced arm, which allowed the subject virtually 
unrestricted movement in the operant chamber.  The swivel was connected to a saline 
pump while the animals were in their home cages by a piece of polyvinyl tubing.  The 
tubing was cut and a luer lock connection was inserted in to the line in order to allow for 
easy transportation of the animals from their home cages to the operant chambers.  The 
luer lock connection consisted of a 20 gauge blunted needle inserted into one end of the 
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polyvinyl tubing, and a blunted Vacutainer brand luer adapter inserted into the other end 
of the tubing. 
Subjects were observed immediately following surgery until they regained 
consciousness before being placed into their home cages.  Following surgery, the animals 
were allowed to recover for 7 days before experimental sessions started.  In order for the 
catheters to remain patent, they were flushed every 90 min with a 2 s infusion of 
heparnized saline (1.7U/ml; 266.67µl/hr) while the animals were in their home cages.  
The patencies of the catheters were checked every two weeks with sodium methohexital 
(Brevital, 0.2 ml/injection).  If the catheters were still patent, the animals would lose 
consciousness shortly after injection of sodium methohexital.   
Procedure 
The subjects were removed from their home cages and placed into the operant 
chamber at the start of the experimental sessions.  Prior to surgery, lever pressing was 
shaped by successive approximation on the active lever located on the front wall of the 
chamber. Responses on the active lever resulted in the delivery of a food pellet (Noyes 
45mg pellets) on a FR 1, 60 s TO schedule of reinforcement.  Following acquisition of 
responding on the active lever the animals underwent surgery as described above.  After 
recovery from surgery, the subjects were given experimental sessions during which food 
reinforcement was replaced by infusions of nicotine.  All other aspects of the schedule 
remained the same.  
On the first day of experimental sessions in which nicotine maintained behavior, 
the number of infusions obtained within a session was limited to 10.  This was done in 
order to limit the subjects’ exposure to any toxic effects from an overdose of nicotine.  
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Acquisition of nicotine self-administration progressed in the order of FR 1 for the first 
five experimental sessions, FR 2 for the next three sessions, and FR 3 for the remainder 
of the experiment.  All active lever presses resulted in an infusion of nicotine bitartrate 
(free base) at a dose of 0.03 mg/kg/inf.  Each dose of nicotine was delivered in 50 µl at 
100 µl/sec.  
During experimental sessions the jeweled lights above both levers and the house 
light were on and white noise was fed into the chambers.  Responses on the active lever 
resulted in a brief flash of the jeweled lights and a feedback click.  After completion of 
the ratio, an infusion of nicotine was delivered through the catheter; the jeweled lights 
and houselight were darkened with the onset of a tone for the duration of the 60 s TO.  
Responses during the timeout were recorded but had no scheduled consequences. 
Responses on the inactive lever (“back responses”) were recorded throughout the entire 
session and had no scheduled consequences.  Upon completion of the 60 min session, the 
catheters were disconnected from the infusion pump and flushed with .1 ml of heparnized 
saline.  The subjects were then removed from the chamber and placed back into their 
home cages.  Approximately 20-25 min following the experimental sessions, the subjects 
were feed 13-15 g of rat chow.  
Stable responding was defined as having 5 or more infusions within an 
experimental session for 5 consecutive sessions, without any obvious increasing or 
decreasing trends over the 5 sessions.  Once stable responding was maintained by 
nicotine on the FR 3 schedule, subjects received intraperitoneal (i.p.) injections of 
Bupropion HCL (0, 10 mg/kg, 30 mg/kg, 56 mg/kg) 15 min prior to an experimental 
session.  After 15 min had elapsed, the subjects were placed into the operant chambers, 
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connected to the infusion pumps, and allowed to complete a session.  Additional 
injections of bupropion were not studied until the number of nicotine infusions returned 
to five or more for two consecutive sessions.  If any of the subjects did not reach criterion 
by the third day following an injection, they were given more experimental sessions until 
they reach the preceding criterion.   
Each dose of bupropion was administered in a pseudorandom order.  The dose of 
bupropion was randomly chosen with the constraint that once a particular dose of 
bupropion was administrated all other doses in the dose effect curve must be 
administered before the dose was repeated.  Once all doses were administrated, the dose 
response curve was again tested starting with saline, as long as the animal’s catheter 
remained patent. 
METHODS – FOOD-DEPRIVED EXPERIMENT 
Subjects 
 
Four Fisher 344 rats were used as subjects in this study.  The subjects were 
individually housed in standard hanging metal home cages and were given unlimited 
access to water except during experimental sessions.  The subjects received a restricted 
food diet of 20g of standard rat chow following each daily session.  The animals were 
housed in reverse light-dark cycle (lights on from 19:00 to 07:00). 
Apparatus 
 The same experimental chambers as described in the previous two experiments 
were used. 
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Procedure    
 Lever pressing on the active lever was shaped by successive approximations, and 
resulted in the delivery of a food pellet (45 mg).  Once the lever-press response was 
acquired, the subjects were placed on an FR 1 60 s TO schedule of food reinforcement.  
The schedule of reinforcement was increased to an FR 3 60 s TO, then to a terminal 
schedule of FR 5 60 s TO.  During each 60 min session, the jeweled lights above both 
levers were illuminated and white noise was fed into the chambers.  Responses on the 
active lever resulted in a brief flash of the jeweled lights and a feedback click.  After 
completion of the ratio, the food pellet was delivered and the jeweled lights were 
darkened, the house light and tone turned on for 20 s.  Following 20 s, the house light and 
tone shut off and the chamber remained dark for the remaining 40 s. of the timeout 
period.  Responses during the timeout were recorded but had no scheduled consequence. 
Responses on the inactive lever were also recorded throughout the entire session and had 
no scheduled consequences.  
 Once the number of reinforcers obtained within a session did not fluctuate by 
more then 2 reinforcers for five consecutive sessions, the subjects received intraperitoneal 
(i.p.) injections of bupropion (0, 10, 30, 56 mg/kg) 15 min prior to the experimental 
session.    After 15 min had elapsed, the subjects were placed into the operant chamber 
and allowed to complete the sessions.  Following a dose of bupropion, the number of 
reinforcers obtained within a session had to be within two reinforcers of the number of 
reinforcers obtained on the day prior to the drug session before another dose of bupropion 
was administered.  Each dose of bupropion was administered at least twice in 
pseudorandom order, as previously described. 
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METHODS - FOOD-SATIATED EXPERIMENT 
Subjects 
Four male Sprague Dawley rats with an age of approximately one month were 
used in this study.  The subjects were individually housed in standard hanging metal 
home cages and had unlimited access to water except during experimental sessions.  The 
subjects received 25 g of standard rat chow for 1.5 hrs immediately prior to their daily 
sessions.  The animals were housed on a reverse light-dark cycle (lights on from 19:00 to 
07:00). 
Apparatus 
 The same experimental chambers were used as previously described in the 
nicotine experiment. 
Procedure 
 Subjects were not fed for 24 hrs prior to an experimental session in which the 
lever-press response on the active lever was shaped by successive approximations.  Each 
lever-press resulted in the delivery of a 45 mg food pellet.  Once the lever-press response 
was acquired, the animals were placed on the same FR1 60 s TO schedule of 
reinforcement previously used for the nicotine experiment, with the exception that food 
pellets maintained behavior instead of nicotine infusions throughout the entire study.  The 
subjects progressed, in a manner identical to the subjects described in the nicotine study, 
to a terminal schedule of FR3 60 s TO.  All discriminative stimuli and stimuli changes 
were identical to the changes that occurred in the nicotine study.    
While the animals were in the experimental chambers completing the 
experimental sessions, the amount of remaining food was weighed to determine the 
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amount of food that had been consumed.  The subjects consumed an average of 16.61 g 
of food with a standard deviation of 4.34 g prior to the session.  Once the remaining food 
was weighed, it was discarded.  Following the sessions, the animals were placed back 
into their home cages and not fed until 1 and ½ hrs prior to the next day’s experimental 
session. 
Once stable responding was established under the preceding conditions, subjects were 
given intraperitoneal (i.p.) injections of bupropion (0, 10, 30, and 56 mg/kg) 15 min prior 
to the experimental session.  Stable responding was determined by visual inspection of 
graphs displaying the number of reinforcers obtained in each daily session.  The graphs 
were observed to make sure that no upward or downward trend could be seen.  Following 
the 15 min pretreatment, the subjects were placed in the experimental chambers and 
allowed to complete the 60 min sessions.  Another dose of bupropion was not 
administered for at least two sessions, with the stipulation that no obvious trend could be 
seen by visual inspection of the graphs for number of reinforcers obtained within the 
sessions, and that the number of reinforcers returned to within the range of that seen prior 
to the previous injection.  The doses were given in a pseudorandom order as previously 
described in the nicotine study until each dose was given twice. 
Drugs 
The drugs used in this study were nicotine di-d-titrate (free base), and 2-(tert-
Butylamino)-3’-chloropropio-phenone Fumarate (bupropion) RTI-6037-41.  Nicotine 
was purchased from RBI, dissolved in heparinized 0.9% injection sodium chloride.  
Nicotine was dissolved in a solution that allowed the drug to be delivered at a dose of 
0.03 mg/kg of the animal’s body weight at a volume of 50 µl at 100 µl/s.  Bupropion was 
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purchased from RTI, and dissolved in 0.9% bacteriostatic sodium chloride in a volume of 
2.0 ml per mg of the drug the evening before an injection.  Each dose of the drug was 
studied at least twice in each animal.     
Data Analysis 
 An alpha level of .05 was used for all statistical tests.  The data were analyzed by 
conducting oneway ANOVAs on the dose-response curves of bupropion for the four 
dependent variables that were measured during the experimental sessions for both the 
group averages of the three different studies and all the individual subjects. The main 
dependent variables of interest were number of reinforcers delivered during the session, 
overall response rate (responses/second), inactive lever response rate (responses/second, 
from this point on referred to as back response rate), and the number of timeout responses 
made per reinforcement opportunity (number of TO responses/number of reinforcers 
obtained within the session).  If the oneway ANOVA was found to be significant, a post 
hoc analysis was done.  A Bonferroni post hoc test was used for all post hoc analysis.  If 
the effect could not be found with a Bonferroni test (a more conservative test), a Least 
Squared Difference (a more liberal test) test was used to determine which dose was 
having a significant effect.  If a Least Squared Difference test was required to find the 
significant effect, then the letters LSD will precede the symbols on the graph.  
 Cumulative response records were collected to determine the pattern of 
responding as it varied across the different doses of bupropion.  The cumulative records 
were also used to assess differences in the patterns of behavior related to the different 
conditions among the three different studies.   
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The data were analyzed looking at the percentage of change from control 
following administration of doses of drug as a function of the control rate of behavior for 
the three rates of behavior (overall response rate, back lever response rate, and timeout 
response rate) for all three studies.  The percent of control for each drug dose (0, 10, 30, 
and 56 mg/kg) was plotted on a log scale against the control rate of the behavior that was 
also plotted on a log scale; these graphs are referred to as rate-dependency plots.  To 
calculate percent control, the rate of the behavior following drug administration at each 
dose was divided by the control rate of that behavior, with the product then multiplied by 
100.  The percent control was then plotted on a log scale against the control rate, which is 
also on a log scale.  Trend lines were fit to the data points on each graph and the r2 value 
for the trend line was displayed on the graph.  This analysis was done for each study, for 
each dose administered, and for all three studies. 
The final type of analysis that was conducted was the percent control of the 
overall response rate (resp/sec) (same as previously described) as a function of bupropion 
dose for each of the three studies.  This analysis resulted in dose response curves in 
which percent control was plotted against the dose of the drug for the nicotine group, 
food-satiated group, and the food-deprived group.  Oneway ANOVAs and post hoc 
analyses were run between the three studies and within studies across the different doses 
of bupropion.    
RESULTS – NICOTINE EXPERIMENT 
 The group averages for the dose effect curves for the effects of bupropion on 
nicotine self-administration are shown in Figure 1.  Bupropion tended to increase the 
overall response rate at the two highest doses administered with the peak effect being at  
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Figure 1. The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf).  The four dependent measures depicted include; overall response rate 
(a.), the number of nicotine infusions obtained or reinforcers (b.), the back lever response 
rate (c.), and the number of timeout responses per reinforcement (d.).  The closed circles 
represent group averages from seven rats and the error bars indicate + -1 standard 
deviation of the mean.  * significantly different from control, ** different from saline, 
*** different from 10 mg/kg, + different from 30 mg/kg, ++ different from 56 mg/kg, 
+++ different from all other conditions.  P< 0.05. 
   
    
the 30 mg/kg dose.  There was a main effect of dose for overall response rate found with 
a oneway ANOVA, F(4, 77) = 3.773, p = .007.  The results for all the post hoc analyses 
are illustrated on the figures with corresponding symbols which are explained in the 
caption.  The 30 mg/kg dose of bupropion tended to increase the number of infusions 
obtained within a session.  There was a main effect of bupropion dose found for the 
number of reinforcers obtained within a session, F(4, 77) = 6.699, p = .000.  Bupropion 
also increased the back lever response rate at the highest dose administered, F(4, 77) = 
5.729, p = .000.  Furthermore, there were dose-dependent increases in the number of 
timeout responses per reinforcement, F(4, 77) = 6.216, p = .000. 
Figure 2 shows the dose effect curves for bupropion on nicotine self-
administration in a single representative subject (Bup30).  Bupropion tended to increase 
both the overall response rate and the number of reinforcers at the moderate and high 
dose tested. There was a significant effect of dose on the overall response rate, and 
number of reinforcers for Bup30, F(4, 9) = 6.635, p = .009, F(4, 9) = 6.7, p = .009, 
respectively.  The drug increased back lever responding at the 56 mg/kg dose, F(4, 9) = 
18.196, p = .000.  For subject Bup30 bupropion also resulted in dose-related increases in 
the number of timeout responses per reinforcement; this main effect of dose was found to 
be significant, F(4, 9) = 9.191, p = .003.  The effects of bupropion on the dependent 
measures for subject Bup52 are illustrated in Figure 3.  The 30 mg/kg dose of bupropion 
tended to increase both the overall response rate and the number of reinforcers obtained, 
although there was a considerable amount of variation between different administrations 
of these doses.  There were no consistent effects of the drug on the back lever response  
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Figure 2.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for rat Bup30.  The closed circles represent averages of two or more 
administrations at each dose, the error bars indicate + - 1 standard deviation of the mean.  
For explanation of symbols, refer to Figure 1.  
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Figure 3.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for subject Bup52.  For description of the graphs, refer to Figure 2. 
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rate, or the number of timeout responses per reinforcement for Bup52.  There were no 
significant effects of drug dose on any of the dependent measures for subject Bup52. 
  Figure 4 shows the data obtained for subject Bup58.  For Bup58 only two of the 
dose effect curves had significant effects; overall response rate and back lever response 
rate.  There was a main effect of dose on overall response rate for Bup58, F(4, 11) = 
4.040, p = .030.  This effect resulted from saline consistently increasing response rate 
while doses of bupropion failed to have consistent effects.  Although doses of bupropion 
did not contribute to the effect found in overall response rate, the moderate dose of the 
drug increased responding on the back lever and resulted in a main effect of dose, F(4, 
11) = 31.494, p = .000. 
 The effects of bupropion on the four dependent variables for subject Bup51 are 
shown in Figure 5.  Bupropion again tended to increase the overall response rate and 
number of reinforcers at the middle and high dose.  These effects were significant for 
Bup51, F(4, 8) = 10.415, p = .003, F(4, 8) = 28.684, p = .000, respectively.  There was 
also a main effect of drug on the number of timeout responses per reinforcement with the 
drug dose-dependently increasing timeout responses, F(4, 8) = 11.408, p = .002.  The 
dose-effect curve for bupropion on back lever responding, for Bup51, resulted in a U-
shaped function although the effects were not significant.  Figure 6 shows the effects of 
bupropion on nicotine self-administration for subject Bup36.  There were no statistically 
significant results for the four dependent variables for Bup36.  However, Figure 6 does 
illustrate a trend for the 30 mg/kg dose of bupropion to increase overall response rate and 
number of reinforcers obtained within a session.  Bupropion did not alter back-lever 
responding or the number of timeout responses for Bup36. 
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Figure 4.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for subject Bup58.  For description of the graphs, refer to Figure 2. 
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Figure 5.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for rat Bup51.  For description of the graphs, details refer to Figure 2. 
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Figure 6.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for rat Bup36.  There was only one administration of both the 10 and 56 
mg/kg doses of the bupropion for this subject due to catheter failure.  For description of 
the graphs, refer to Figure 2. 
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The effects of bupropion for subjects Bup57 and Bup59 are shown in Figures 7 
and 8, respectively.  Post hoc analyses were not run on these two subjects because the 
dose-effect curve of bupropion was only administered once before their catheters lost 
patency.  Figures 7 and 8 again illustrate the increasing effect of the moderate dose of 
bupropion on both the overall response rate and the number of reinforcers for both 
subjects. 
The cumulative response records for subjects Bup30 and Bup51 are shown in 
Figures 9, 10, 11, and 12.  These records were selected because the graphs best represent 
the overall effects of bupropion on nicotine self-administration.  The cumulative response 
records for subject Bup30 are shown in Figures 9 for control days (the day prior to an 
injection), and saline, and in Figure 10 for the 10, 30, and 56 mg/kg doses of bupropion.  
Explanation of the records can be found in the Figure 9 caption.  The increase in nicotine 
self-administration after the administration of the moderate and high dose of bupropion 
are clearly evident by the increased height of the y-axis and more pen displacements in 
the 30 and 56 mg/kg graphs compared to saline or control graphs.  The increase in back-
lever response rate can also be seen by the increased number of diagonal displacements 
on the bottom line for both the 30 and 56 mg/kg records.  The increase in the number of 
timeout responses is represented by the pen stepping up during timeout periods for both 
the 30 and 56 mg/kg records.  The cumulative response records for subject Bup51 are 
shown in Figures 11 and 12 for control, saline, and drug conditions.  Again, the increases 
in nicotine self-administration following the administration of the 30 and 56 mg/kg doses 
of bupropion are illustrated by the increase in the height of the y-axis and the number of 
pen displacements for this subject. 
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Figure 7.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for subject Bup57.  There was only one administration of the 10, 30, and 
56 mg/kg doses of bupropion for this subject due to catheter failure.  For description of 
the graph, refer to Figure 2. 
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Figure 8.  The effects of bupropion (10, 30, 56 mg/kg) on nicotine self-administration 
(0.03 mg/kg/inf) for subject Bup59.  There was only one administration of the 10, 30, and 
56 mg/kg doses of bupropion for this subject due to catheter failure.  For description of 
the graph, refer to Figure 2. 
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Figure 9.  Cumulative response records of subject Bup30 self-administering nicotine 
(0.03 mg/kg/inf) under control, saline conditions.  Each response by the subject on the 
active lever results in the vertical movement of the pen.  Upon completion of the ratio the 
pen was diagonally displaced indicating the delivery of the reinforcer, the pen remained 
displaced down during the 60 s TO following reinforcement.  The vertical movement of 
the pen while in the displaced position indicates responses on the active lever during 
timeout periods.  Following the completion of the 60 s TO the pen was reset to its normal 
position.  On the lower event line, any displacement of the event pen indicates a response 
on the back lever.  
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Figure 10.  A representative cumulative response record for subject Bup30 following 
administration of various doses of bupropion (10, 30, and 56 mg/kg). 
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Figure 11.  Cumulative response records for subject Bup51 self-administering nicotine 
(0.03 mg/kg/inf) under control, saline conditions.  For description of the cumulative 
response, records refer to Figure 9. 
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Figure 12.  A representative cumulative response record for subject Bup51 following 
administration of various doses of bupropion (0, 10, 30, and 56 mg/kg). 
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To further elucidate the effects of bupropion, the data were analyzed for rate-
dependent effects on back-lever response rate, timeout response rate, and overall 
response rate.  Figure 13 shows the rate-dependency plots for these three different 
behaviors for saline and 10 mg/kg injections.  In the rate-dependency plots, the percent 
control is plotted on the y-axis against the control rate of responding plotted on the x-
axis.  Saline and the 10 mg/kg dose resulted in flat trend lines and majority of points 
around control levels.  Figure 14 contains the rate-dependency plots for the three different 
behaviors following injections of 30 and 56 mg/kg doses of bupropion.  These plots 
indicate that bupropion was not resulting in rate-dependent effects within the nicotine 
study.   
RESULTS – FOOD-DEPRIVED EXPERIMENT 
 Figure 15 shows the group averages for the effects of bupropion on food-deprived 
animals under a FR5 60 s TO schedule of food reinforcement.  Bupropion tended to 
slightly increase the overall response rate at the low dose, while the moderate and high 
doses resulted in dose-dependent decreases in the overall rate of response. The highest 
dose of bupropion decreased the number of reinforcers obtained within the session.  The 
effects of the drug on the overall response rate and the number of reinforcers were found 
to be significant, F(4, 56) = 11.923, p = .000, and F(4, 56) = 12.289, p = .000, 
respectively.  Bupropion also resulted in a dose dependent increase in the number of 
timeout responses per reinforcement, F (4, 56) = 3.000, p = .026.  However, there were 
no significant effects of drug on back-lever responding.  The dose-effect curves for 
subject Bup9 are shown in Figure 16.  The moderate and high dose of bupropion resulted  
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Figure 13.  Rate dependency plots of the three ongoing rates of behavior; timeout 
response rate (Nicotine TO), back lever response rate (Nicotine Back), and the overall 
response rate (Nicotine Overall).  All rates are expressed in terms of the percentage of 
control plotted against the control rate of the subject.  Trend lines are fit to all data points, 
the r2 values for the trend lines are illustrated on each graph. The figure illustrates the 
effects following saline administration and 10 mg/kg dose of bupropion for seven rats 
self-administering nicotine. 
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Figure 14.  Rate dependency plots for seven rats following the administration of 30, and 
56 mg/kg doses of bupropion.  For description of the graph, refer to Figure 11. 
 
 
 
 43  
    
Bupropion Dose (mg/kg)
Con Sal 10 30 56
O
ve
ra
ll 
R
at
e 
(re
sp
/s
ec
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Bupropion Dose (mg/kg)
Con Sal 10 30 56
B
ac
k 
Le
ve
r R
es
po
ns
e 
R
at
e 
(r
es
p/
se
c)
0.00
0.01
0.02
0.03
0.04
a. 
0.0
c. 
5
Bupropion Dose (mg/kg)
Con Sal 10 30 56
R
ei
nf
or
ce
rs
0
10
20
30
40
50
60
70
Bupropion Dose (mg/kg)
Con Sal 10 30 56
TO
 R
es
po
ns
es
 p
er
 R
ei
nf
or
ce
m
en
t
0
5
10
15
20
*
**
***
+++
LSD
*
LSD
*
Food Deprived Group Averages
N = 4
Food Deprived Group Averages
N = 4
Food Deprived Group Averages
N = 4
Food Deprived Group Averages
N = 4b.
d.
 
 
Figure 15.  The effects of bupropion (10, 30, 56 mg/kg) on behavior maintained by an 
FR5 60 s TO schedule of reinforcement in food-deprived animals.  The closed circles 
average for the four rats, the error bars indicate +- 1 standard deviation of the mean.  For 
further description of the graphs, refer to Figure 1. 
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Figure 16.  The effects of bupropion (10, 30, 56 mg/kg) on food-maintained behavior 
under food derivation conditions for subject Bup9.  For description of graph, refer to 
Figure 1. 
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in dose-dependent decreases in the overall response rate and the number of reinforcers, 
while having no consistent effect on back-lever responding or timeout responses.  A 
statistical analysis of this subject’s data revealed a significant effect of drug on the overall 
response rate, F(4, 11) = 6.760, p = .005, and the number of reinforcers obtained within a 
session, F(4, 11) = 30.338, p = .000.  Figure 17 shows the dose-effect curves for subject 
Bup10.  Again there were significant dose-related effects on overall response rate, F(4, 4) 
= 8.049, p = .034, and number of reinforcers, F(4, 4) = 271.040, p = .000.  For subject 
Bup10 there were also a significant dose-related increases in back-lever responding, F(4, 
4) = 66.911, p = .001, and timeout responses, F(4, 4) = 6.959, p = .043.   
Figure 18 contains the dose-effect curves for subject Bup11.  There was again 
significant dose-dependent decreases on the overall response rate (F(4, 16) = 9.131, p = 
.000.) and the number of reinforcers (F(4, 16) = 47.669, p = .000.) for this subject, while 
there was no significant effect of the drug on the back-lever responding or timeout 
responses.  Figure 19 shows the effects of bupropion on the four dependent measures for 
subject Bup12.  For this subject there was again a significant effect of the drug on the 
overall response rate and the number of reinforcers obtained, while there was no 
significance of the drug’s effects on back-lever responding or timeout responses.  There 
was a significant rate-decreasing effect of bupropion on the overall response rate,  
F(4, 10) = 6.381, p = .008, as well as a drug decreasing effect on the number of 
reinforcers obtained within a session, F(4, 16) = 8.877, p = .003. 
 Figures 20, 21, and 22 contain representative cumulative response records of 
subject Bup10 from control, saline, and the three different doses of bupropion.  The much 
steeper slope of the lines indicates a higher rate of behavior maintained under the food-  
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Figure 17.  The effects of bupropion (10, 30, 56 mg/kg) on food-maintained behavior 
under food derivation conditions for subject Bup10.  For description of the graph, refer to 
Figure 1. 
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Figure 18.  The effects of bupropion (10, 30, 56 mg/kg) on food-maintained behavior 
under food derivation conditions for subject Bup11.  For description of graph, refer to 
Figure 1. 
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Figure 19.  The effects of bupropion (10, 30, 56 mg/kg) on food-maintained behavior 
under food derivation conditions for subject Bup12.  For description of graph, refer to 
Figure 1. 
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Figure 20.  Cumulative response record of a representative subject’s (Bup10) behavior on 
an FR5 60 s TO schedule of food reinforcement under control and saline conditions.  
Descriptions of the cumulative records are found in Figure 9. 
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Figure 21.  Cumulative response record of a representative animal’s (Bup10) behavior on 
an FR5 60 s TO schedule of food reinforcement under drug conditions.  Descriptions of 
the cumulative records are found in Figure 9. 
 
 51  
    
 
50
 R
es
po
ns
es
 
10 Min 
56 mg/kg 
 
 
Figure 22.  Cumulative response record of a representative animal’s (Bup10) behavior on 
an FR5 60 s TO schedule of food reinforcement following administration of 56 mg/kg 
dose of bupropion.  Descriptions of the cumulative records are found in Figure 9. 
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deprived conditions compared to the nicotine study.  In addition, the behavior was fairly 
consistent across the low and moderate doses.  There was a slight disruption in 
responding at the 30 mg/kg dose of the drug, indicated by a decrease in the slope of the 
line indicating longer run times compared to control conditions. A small increase in the 
number of timeout responses is shown by the increase in the slope of the line while the 
pen is displaced near the end of the timeout periods.  At the 56 mg/kg dose (Figure 22) of 
the drug, a large disruption in responding can be seen.  The decrease in the overall 
response rate is indicated by an increase in the run times and, as a result, a decrease in the 
slope of the line compared to control levels.  The increase in the number of timeout 
responses is shown by the dramatic increase in the slope of the line while the pen was 
displaced.  The increase in back-lever responding is indicated by the increase in the 
number of pen displacements on the event line. 
The rate-dependency plots for the food-deprived study are shown in Figures 23 
and 24.  Again, the percent control is plotted on the y-axis against the control rate that is 
plotted on the x-axis.  Figure 23 shows the rate-dependency plots following saline and the 
10mg/kg administration of bupropion.  Saline and the low dose of bupropion did not 
result in a rate-dependent effect on behavior; this is illustrated by the majority of points 
falling around 100 percent.  There was very little deviation from control rates although 
the 10 mg/kg dose of bupropion did tend to decrease back-lever responding.   Figure 24 
illustrates the rate-dependency plots for the effects of the two highest doses of bupropion 
on the three behaviors.  The moderate dose of bupropion again did not result in any rate-
dependent effects as indicated by the relatively flat trend line fit to the data points.  The 
rate dependency plot for the 56 mg/kg dose of bupropion indicates a rate-dependent  
 53  
    
Saline
C ontro l R ate (resp/sec)
0.0001 0.001 0.01 0.1 1 10
P
er
ce
nt
 C
on
tro
l
1
10
100
1000
10000 Food D eprived T O
Food D eprived Back
Food D eprived O verall
r ² = 0 .0149
10 m g/kg
C ontro l R ate  (resp/sec)
0.0001 0.001 0.01 0.1 1 10
P
er
ce
nt
 C
on
tro
l
1
10
100
1000
10000
r ² = 0.1953
 
 
Figure 23.  Rate dependency plots of the three behaviors; timeout response rate (Food 
Deprived TO), back lever response rate (Food Deprived Back), and the overall response 
rate (Food Deprived Overall).  All rates are expressed in terms of the percentage of 
control plotted against the control rate of the subject.  Trend lines were fit to all data 
points; the r2 values for the trend lines are illustrated on each graph.  The figure illustrates 
the effects following saline administration and 10 mg/kg dose of bupropion for four rats 
on an FR5 60 s TO of food reinforcement under deprivation conditions. 
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Figure 24.  Rate dependency plots for four rats on the FR5 60 s TO schedule of food 
reinforcement under deprivation conditions, following the administration of 30, and 56 
mg/kg doses of bupropion.  For description of the graph, refer to Figure 21. 
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effect of the drug. The rate-dependent effect of the highest dose of the drug is 
demonstrated by the high amount of variance accounted for by the regression line fit to 
the data (r2 = .7324).  The 56 mg/kg dose of the drug tended to increase the lowest and 
moderate rates of responding (back-lever responding and timeout responding, 
respectively), while decreasing the highest rate of responding (overall response rate).   
RESULTS-FOOD-SATIATED EXPERIMENT 
The group averages for the dependent measures of the four subjects in the food-
satiated study are shown in Figure 25.  Bupropion tended to slightly increase the overall 
response rate and the number of reinforcers obtained for the group for both the 10 and 30 
mg/kg doses, while the highest dose of 56 mg/kg decreased the overall response rate and 
the number of reinforcers for the group.  The effect of dose on the overall response rate 
was found to be significant (F(4, 53) = 2.799, p = .030).  The effect of the drug on the 
number of reinforcers obtained was also found to be significant (F(4, 53) = 9.493, p = 
.000).  Bupropion had no consistent effect on back-lever responding.  The number of 
timeout responses for the group significantly increased at the medium and high doses of 
the drug, F(4, 51) = 5.122, p = .002. 
Figure 26 illustrates the effects of bupropion on the four dependent measures for 
subject Bup60.  Bupropion increased both the overall response rate and the number of 
reinforcers obtained within the session when compared to saline at the 10 and 30 mg/kg 
doses; these effects were found to be significant, F(4, 9) = 4.853, p = .023, and F(4,9) = 
7.599, p = .006, respectively.  The high dose of bupropion tended to increase both the 
back-lever response rate as well as the number of timeout responses.  The effect of the 
drug on the back-lever response rate was significant (F(4, 9) = 7.433, p = .006).  The  
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Figure 25.  The effects of bupropion (10, 30 ,56 mg/kg) on behavior maintained by an 
FR3 60 s TO schedule of reinforcement in four food satiated animals.  The closed circles 
are averages of four rats, the error bars indicate +- 1 standard deviation of the mean.  For 
further description of the graphs, refer to Figure 1. 
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Figure 26.  The effects of bupropion on food-maintained behavior under the food satiated 
condition for subject Bup60.  For description of graph, refer to Figure 1. 
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effect of the drug on the number of timeout responses was also significant (F(4, 9) = 
7.599, p = .006). 
Figure 27 shows the influence of the drug on four dependent variables for subject 
Bup61.  Bupropion increased the overall response rate at the medium dose while the 
higher dose of the drug decreased response rate.  These effects were found to be 
statistically significant (F(4, 9) = 4.533, p = .028).  The high dose of bupropion had a 
significant decreasing effect on the number of reinforcers obtained within session (F(4, 9) 
= 8.880, p = .003).  Bupropion increased back-lever responding at the high dose of the 
drug (F(4, 9) = 6.589, p = .009).  Bupropion also tended to increase the number of 
timeout responses per reinforcement at the moderate dose of the drug although this effect 
was not significant (F(4, 9) = 2.198, p = .150).   
 Figure 28 depicts the effects of the drug for the four dependent measures for 
subject Bup62.  Bupropion had no consistent effects on the overall response rate, number 
of reinforcers, and the back-lever response rate, although there was a slight decrease in 
the back-lever response rate at the largest dose of bupropion for subject Bup62, F(4, 9) = 
.081, p = .986, F(4, 9) = .509, p = .731, F(4, 9) = .306, p = .867, respectively.  Bupropion 
did have a dose-dependent increase in the number of timeout responses per 
reinforcement; this effect was found to be significant, F(4, 9) = 14.315, p = .001. 
 Figure 29 illustrates the effects of bupropion on the four dependent measures for 
Bup63.  Bupropion had no significant effect on the overall response rate, with the 
exception that the high dose completely suppressed responding for this subject F(4, 9) = 
1.608, p = .254.  Bupropion resulted in a significant dose-dependent decrease in the 
number of reinforcers obtained within the session (F(4, 9) = 19.105, p = .000).  The drug  
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Figure 27.  The effects of bupropion (10, 30,56 mg/kg) on food-maintained behavior 
under the food satiated condition for subject Bup61.  For description of graph, refer to 
Figure 1. 
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Figure 28.  The effects of bupropion (10, 30, 56 mg/kg) on food-maintained behavior 
under the food satiated condition for subject Bup62.  For description of graph, refer to 
Figure 1. 
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Figure 29.  The effects of bupropion (10, 30, 56 mg/kg) on food-maintained behavior 
under food satiated conditions for subject Bup61.  For description of graph, refer to 
Figure 1. 
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did not have consistent effects on back-lever responding.  Bupropion resulted in an 
inverted U-shaped dose-response curve for the number of timeout responses for this 
subject (F(4, 9) = 3.814, p = .044).  The behavior under saline and drug conditions for 
subject Bup60 best represented the group averages, so cumulative response records of 
this subject are shown in Figures 30 and 31.  The increase in overall response rate at the 
10 and 30 mg/kg doses is illustrated by the increase in slope seen in the two cumulative 
response records when compared to saline and control conditions.   The increase in 
timeout responses can also be seen by the increase in the slope of the line while the pen is 
in the displaced position.  The decrease in the overall response rate at the highest dose of 
bupropion is illustrated by the decrease in the slope of the line near the end of the session. 
 The rate-dependency plots for the food-satiated group are illustrated in Figures 32 
and 33.  The rate-dependency plots have the percent control on the y-axis plotted against 
the control rate plotted on the x-axis.  Figure 32 shows the rate-dependency plots under 
saline and the 10 mg/kg dose of bupropion.  The rate-dependency plots in Figure 32 again 
illustrate that saline and the lowest dose of bupropion are not affecting behavior in a rate-
dependent manner, as indicated by points for all behaviors in both graphs falling around 
100 percent.  Figure 33 contains the rate-dependency plots of the behaviors following the 
administration of the moderate and highest doses of bupropion.  The small r2 values for 
the both the 30 and 56 mg/kg doses indicate that bupropion did not have rate-dependent 
effects.  The 30 mg/kg graph shows that at the moderate dose of bupropion tested points 
continued to stay around 100 percent, with only the timeout responding showing a slight 
increase from 100 percent.  Data following the administration of the 56 mg/kg dose  
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Figure 30.  Cumulative response record of subject’s Bup60 responding on an FR3 60 s 
TO schedule of food reinforcement under control, saline, and 10 mg/kg drug conditions.  
Descriptions of the cumulative records are found in Figure 9. 
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Figure 31.  Cumulative response record of subject’s Bup60 responding on an FR3 60 s 
TO schedule of food reinforcement following the administration of 30 and 56 mg/kg 
doses of bupropion.  Descriptions of the cumulative records are found in Figure 9. 
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Figure 32.  Rate dependency plots of the three behaviors; timeout response rate (Food 
Satiated TO), back lever response rate (Food Satiated Back), and the overall response rate 
(Food Satiated Overall).  All rates are expressed in terms of the percentage of change 
from control plotted against the control rate of the subject.  Trend lines are fit to all data 
points; the r2 values for the trend lines are illustrated on each graph.  The figure illustrates 
the effects following saline administration and 10 mg/kg dose of bupropion for four rats 
on an FR3 60 s TO of food reinforcement under satiated conditions. 
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Figure 33.  Rate dependency plots for four rats on an FR3 60 s TO of food reinforcement 
under satiated conditions, following the administration of 30 and 56 mg/kg doses of 
bupropion.  For description of the graph, refer to Figure 30. 
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indicate that behavior following the administration of this dose was much more variable 
across animals but no rate-dependent trends in the data were found. 
In order to make comparisons across the three different studies, the overall 
response rates for each group of animals, following the administration of saline and the 
doses of bupropion (10, 30, 56 mg/kg), were converted into percent control and are 
displayed in Figure 34.  For graphs in Figure 34 an increase above 100 indicates that the 
drug increased overall response rates above control levels, while points plotted below 100 
illustrate that the drug had a decreasing effect on these rates.  Figure 34 shows that the 30 
mg/kg dose of bupropion increased the mean overall response rate (average control rate, 
0.012 resp/sec) maintained by nicotine self-administration (F(3, 24) = 3.037, p = .049).  
There was also a non-significant trend for the moderate dose of bupropion to increase 
behavior maintained by food-reinforcement when the animals’ overall response rates 
were decreased through food satiation (average control rate, 0.488 resp/sec), F(3, 12) = 
2.970, p = .074.  However, this effect was not as pronounced as the effect on nicotine.  
Figure 34 also revealed that when bupropion was administered to subjects on a similar 
food reinforcement schedule but under deprived condition (i.e. resulting in higher 
response rate, average control rate 1.377 resp/sec), the 30 mg/kg dose of bupropion 
resulted in rate-decreasing effects, F(3, 12) = 23.876, p = .000.   
 In order to determine whether there were any differences in the effects of 
bupropion between the three different studies, analyses were conducted on the percent 
control of the overall response rate.  Oneway ANOVAs were conducted on each dose of 
bupropion between the different studies.  Analysis of the 30 mg/kg dose revealed a 
significant effect between studies, F(2, 12) = 5.676, p = .018; no effects were found  
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Figure 34.  The percentage of change in the overall response rate from control rates 
following the administration of doses of bupropion and saline, for the three studies.  The 
open triangles in the nicotine graph are the average of seven data points at each dose (one 
for each rat).  The open circles in the food-satiated graph are the average of four data 
points at each dose (one for each rat).  The open squares in the food-deprived graph are 
also the average of four data points at each dose (one for each rat).  The error bars on all 
three graphs are one standard deviation of the mean.  For description of the symbols, 
refer to Figure 1.     
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between studies for any other doses.  A Bonferroni post hoc test revealed that the increase 
in the overall response rate in the nicotine study following the administration of the 30 
mg/kg dose of bupropion had a significantly different effect from the effect on overall 
response rate in the food-deprived study.  The increasing effect on the overall response 
rate in the nicotine study was not significantly different than from the increase seen in the 
food-satiated study. 
Rate-dependency plots for the three behaviors for all three studies are depicted in 
Figures 35 and 36.  Figure 35 shows the rate-dependency graphs for saline administration 
and 10 mg/kg dose of bupropion.  Again the low r2 values for saline and the 10 mg/kg 
dose of bupropion indicate that the low dose of the drug did not have rate-dependent 
effects.  The rate-dependency plots for the 30 and 56 mg/kg doses, found in Figure 36, 
reveal that the highest dose of bupropion had rate-dependent effects on behavior.  
Bupropion at the highest dose appeared to increase low to medium rates of behavior and 
decreased the higher rates of behavior.  A fair amount of variance can be accounted for 
by the regression line plotted to the data in the 56 mg/kg graph in Figure 36 (r2 = .3507).   
An even more striking correlation can be seen when just the overall response rates 
for the three different studies are presented using rate-dependency plots.  Figure 37 shows 
that there are no rate-dependent effects on the overall response rates following the 
administration of saline or the 10 mg/kg dose of bupropion.  Again, for both saline and 
the low dose of the drug, data remained around 100 percent resulting in a straight trend 
line.  Figure 38 strongly indicates that the overall response rate under control conditions 
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Figure 35.  Rate dependency plots of the three behaviors for all three studies.  The 
symbols and descriptions of the graphs are the same as previously described in Figures 
11, 21, and 30.  The figure illustrates the effects following saline administration and 10 
mg/kg dose of bupropion for all three studies. 
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Figure 36.  Rate dependency plots of the three behaviors for all three studies.  The 
symbols and descriptions of the graphs are the same as previously described in Figures 
11, 21, and 30.  The figure illustrates the effects following the administration of 30 and 
56 mg/kg doses of bupropion for all three studies. 
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Figure 37.  Rate dependency plots of the overall response rates of the three different 
studies.  The symbols and descriptions of the graphs are the same as previously described 
in Figures 11, 21, and 30.  The figure illustrates the effects on overall response rate 
following the administration of saline and the 10 mg/kg dose of bupropion for all three 
studies.
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Figure 38.  Rate dependency plots of the overall response rates of the three different 
studies.  The symbols and descriptions of the graphs are the same as previously described 
in Figures 11, 21, and 30.  The figure illustrates the effects on the overall response rate 
following the administration of 30 and 56 mg/kg doses of bupropion for all three studies. 
 
 
 74  
    
was a determinant for effects of the drug following the administration of the two highest 
doses of bupropion.  When the three overall response rates were plotted against percent 
control for the 30 mg/kg dose a high r2 was found (r2 = 0.6641).  The 56 mg/kg dose of 
bupropion also indicated a large amount of variance that could be accounted for by the 
regression line (r2 = 0.4741).  Bupropion at the 30 mg/kg dose tended to increase the 
lowest overall response rate found in the nicotine study while resulting in a slight 
increase in the moderate response rate found in the food-satiated study.  The 30 mg/kg 
dose of bupropion resulted in a decrease in the highest overall response rate found in the 
food-deprived study.  The 56 mg/kg dose of bupropion had similar effects on the overall 
response rates to that of the moderate dose, yet the results were more variable.   
DISCUSSION 
In the nicotine study, the significant increases in the overall response rate resulted 
in a corresponding significant increase in the number of reinforcers with the apex of the 
dose-effect curve occurring at the 30 mg/kg dose of bupropion.  Administration of 
bupropion in the nicotine study resulted in a dose-dependent increase in timeout 
responding with the significant increase occurring following the administration of the 
highest dose of the drug.  The highest dose of bupropion also resulted in a significant 
increase in back-lever responding in the nicotine study.  The effects of bupropion on the 
three rate measures in the nicotine study did not appear to be dependent on the control 
rate of responding, which was indicated by the flat trend lines in the nicotine rate 
dependency plots. 
The effects of bupropion on food-maintained behavior in food-deprived subjects 
resulted in dose-dependent decreases in both the overall response rate and the number of 
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reinforcers.  For both the overall response rate and the number of reinforcers the 
significant decreasing effects of the drug were found to be statistically significant 
following the administration of the highest dose.  The effects of bupropion on the timeout 
responding in the food-deprived study resulted in dose-dependent increases, with 
significant effects resulting from the administration of both the moderate and highest 
dose of the drug.  Bupropion did not have an effect on back-lever responding in the food-
deprived study.  The effects of the highest dose of bupropion on the three rate measures 
in the food-deprived study appear to be a function of the control rate of the behavior.  
Bupropion tended to increase the low and moderate rates of behavior in the food-
deprived subjects while decreasing the highest rate of behavior. 
When food-maintained behavior occurred at a more moderate rate (i.e. food-
satiated study), bupropion tended to increase the overall rate of response at the low and 
moderate dose of the drug, while only the highest dose of the drug decreased overall 
response rate.  Only the highest dose of bupropion resulted in a decrease in the number of 
reinforcers obtained in session for the food-satiated group.  Bupropion tended to dose-
dependently increase timeout responding with the significant effect resulting from the 
administration of the moderate and highest doses of the drug in the food-satiated study.  
Bupropion failed to have an effect on back-lever responding in the food-satiated study.  
The effects of bupropion on the three rate measures in the food-satiated study appear not 
to be dependent on the control rate of the behavior at the time that the drug is 
administered.  This is evident from the relatively flat trend line in the food-satiated rate-
dependency plots. 
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Bupropion tended to increase the overall response rate maintained by nicotine 
self-administration, with the peak effect following the administration of the 30 mg/kg 
dose.  While an increase in nicotine self-administration was found, bupropion in the food-
deprived study resulted in a dose-dependent decrease in the overall response rate when 
the rates were considerably different.  By satiating the animals, a lower response rate was 
achieved which allowed for the comparisons of the drug’s effects on two more 
comparable rates of responding (i.e., nicotine overall response rate and food-satiated 
overall response rate).  When bupropion was administered to a more comparable rate of 
behavior maintained by food to the rate of nicotine-maintained behavior, the drug 
resulted in similar effects with both reinforcers.  The peak increase in the overall 
response rate in the food-satiated group again resulted after the administration of the 30 
mg/kg dose of bupropion.  When the overall response rates for the different studies were 
investigated to determine whether bupropion was having rate-dependent effects, the 30 
and 56 mg/kg doses of the drug indicated that the effect of the drug was a function of the 
control rate of responding. 
 A striking result from the current studies is the fact that bupropion resulted in an 
increase in nicotine self-administration.  These results would not be suspected from a 
drug that has been shown to have clinical efficacy in furthering smoking cessation (Hurt 
et al., 1997; Jorenby et al., 1999).  The results from the current study are congruent with 
recent study conducted by Rauhut, Neugebauer, Dwoskin, and Bardo, (2003).  In the 
Rauhut et. al. study, bupropion was also found to increase nicotine self-administration in 
rats while decreasing responding maintained by sucrose pellets.  In another recent study 
by Shoaib, Sidhpura, and Shafait (2003), a 30 mg/kg dose of bupropion given chronically 
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to rats for 28 days resulted in an increase in nicotine intake.  The increase in nicotine self-
administration in the Shoaib, et. al. study persisted through the 28 days of treatment. 
  A possible explanation for discrepancy between the results from the clinical 
studies (Hurt et al., 1997; Jorenby et al., 1999) and the current study is in the difference 
in species used.  This does not appear to be a viable explanation for the discrepancy 
between the animal studies and the clinical trial results because it has recently been found 
that acute doses of bupropion, when administered to humans, resulted in an increase in 
the number of cigarettes smoked (Cousins, Stamat, & de Wit, 2001).  The increase in 
cigarette smoking following administration of bupropion was similar to the increase in 
the number of cigarettes smoked following the administration of another stimulant, d-
amphetamine (Cousins et al.).  The results from the current study and Cousins et al. 
indicate that the difference in the dosing regimen of bupropion may have contributed to 
the difference between the current study and the clinical studies. 
A possible reason for the increase in nicotine self-administration following 
administration of bupropion could be that the drug, a dopamine reuptake inhibitor 
(Cooper et al., 1980; Ferris, Maxwell, Cooper, & Soroko, 1982), is having a priming 
effect on nicotine self-administration. That is, bupropion may be blocking the reuptake of 
dopamine in the nucleus accumbens, causing increased levels of extracellular dopamine 
and priming the substrates that are involved in drug reward.  It has been shown that 
animals will self-administer drugs to maintain particular levels of dopamine in the 
nucleus accumbens (Wise et al., 1995).  If bupropion was resulting in an increase in the 
levels of extracellular dopamine in the NA, the subjects could be increasing nicotine self-
administration in an attempt to reach a particular level of dopamine.  A priming 
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interpretation for the increase in nicotine self-administration may not be a viable 
explanation since the administration of bupropion did not result in an increase in 
amphetamine self-administration in the Rauhut et. al. (2003) study.   If bupropion was 
increasing nicotine self administration from priming through the drug’s dopamine 
reuptake mechanism, it would be suspected that the drug would also prime responding 
that was maintained through other reinforcers that result in increase in DA levels in the 
NA.   
Another possibility is that bupropion may be acting as a nicotinic antagonist.  
Recently, bupropion has been found to be a noncompetitive nicotinic antagonist (Fryer & 
Lukas, 1999; Slemmer et al., 2000).  Bupropion blocked the α4β2, α3β2, and the 
α7 nicotinic acetylcholine receptors (Slemmer et al., 2000).  A recent study by Miller, 
Sumithran, and Dwoskin (2002) found that bupropion inhibited nicotine-evoked 
dopamine overflow through the drug’s antagonistic effects at the α3β4 and the α3β2 
nicotinic receptors.  Bupropion could be binding to the nicotinic receptors in the VTA 
and blocking the receptors; this would result in a decrease in the amount of dopamine 
released in the nucleus accumbens.  Thus, bupropion may be blocking the reinforcing 
effects of nicotine and the increase in drug intake is an extinction burst, or the animal’s 
were attempting to override the antagonistic effects of the drug.  If bupropion were 
affecting nicotine self-administration through this mechanism, it would be the first 
antagonist to the author’s knowledge that resulted in an increase in nicotine self-
administration using the rodent model.     
A third possible interpretation of the results of this study is that bupropion may 
not be altering any reinforcing effects of nicotine.  The increase in nicotine self-
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administration could be a behavioral effect of the drug (i.e., rate dependency) not related 
to changes in the reinforcing efficacy of nicotine. Little research has been conducted 
investigating the effects of bupropion on schedule-controlled behavior.  In one study 
investigating the effects of bupropion on behavior maintained by a multiple FI FR 
schedule, it was found that bupropion increased responding in the FI component (lower 
rate of behavior) and had little to no effect on the FR component of the schedule 
(McKearney, 1982).  In another study, bupropion was found to increase low rates of 
responding under a fixed-interval schedule of reinforcement (Spealman, Madras, & 
Bergman, 1989).   
The results from the current studies seem to indicate that bupropion was having 
rate-dependent effects.  The rate-dependency plots of the overall response rates (Figure 
36) for the different groups of animals indicates that the 30 mg/kg and the 56 mg/kg 
doses of bupropion are showing a strong tendency to increase the lower rates found in the 
nicotine study.  The 30 mg/kg dose of bupropion also slightly increased the moderate 
rates found with the food-satiated study, while decreasing the higher rates of behavior 
found in the food-deprived study.  Also, when looking only at the food-deprived group, 
the rate-dependency plot for the 56 mg/kg dose (Figure 22) shows that the largest dose of 
bupropion increased the low and moderate rates of behavior (back response rate and 
timeout response rate, respectively), while decreasing the highest rate of behavior 
(overall response rate).  Also, by visually examining the cumulative record for the 56 
mg/kg dose of bupropion of Bup10 (Figure 20), the decrease in overall response rate can 
be seen with the longer run times as well as the increasing number of timeout responses 
and back-lever responses compared to that of control (Figure 18). 
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The apparent rate-dependent effects of bupropion on nicotine-maintained 
behavior and food-maintained behavior in the current studies are most likely due to the 
response rate rather than the difference in the maintaining event.  The effects of 
stimulants on schedule-controlled behavior have been shown to be a function of the rate 
of response rather then the maintaining event.  In a study by Branch (1979), it was found 
that the effects of cocaine and d-amphetamine were not dependent of the type of event 
maintaining behavior.  In a three-component multiple schedule of food presentation, 
electric shock presentation, and escape responding, Branch found that the acute 
administration of either cocaine or d-amphetamine affected responding in a similar 
manner across all three components.  McKearney (1974) conducted a study that also 
shows that the primary determinant of a stimulant’s effect on schedule-controlled 
behavior is the ongoing rate of behavior rather then the consequent event.  In the study by 
McKearney, similar rates of behavior were maintained on a FI schedules of shock 
presentation and food presentation, as well as on a multiple schedule of food and shock 
presentation.  The administration of d-amphetamine resulted in similar rate-dependent 
effects for behavior that was maintained by shock presentation and food presentation 
under single FI schedules as well as the two schedules in a multiple schedule paradigm.       
The data from the current studies indicate that the increasing effects of bupropion 
on nicotine self-administration may not have resulted from the drug’s effects on the 
nicotinic substrates but rather were influenced by the control rate of responding.  
Although the data indicate a rate-dependent effect of the drug, a more conclusive 
understanding of rate-dependent effects of bupropion could be achieved by looking at the 
drug on a multiple schedule of positive reinforcement.  
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Bupropion may be increasing nicotine self-administration in the current study by 
decreasing the averseness of nicotine.  This interpretation seems unlikely, considering 
that bupropion failed to alter the aversive stimulus effects of nicotine in a conditioned 
taste aversion procedure (Shoaib et al., 2003).  A fifth possible explanation for the 
increase in nicotine self-administration could be that bupropion resulted in a general 
increase in locomotor activity.  Bupropion has been shown to increase locomotor activity 
(Cooper et al., 1980), and in the current nicotine study, a dose-dependent increase in 
back-lever response rate (Figure 1) was seen.  Even though bupropion resulted in an 
increase in back-lever response rates, there was a large amount of variability between 
doses, and the effect was not consistent across all animals in the nicotine study.  Also, an 
increase in back-lever response rate was not seen in either of the two food studies. This 
indicates that the increase in nicotine self-administration may not  be a result of a general 
increase in locomotor activity.  If bupropion was having antagonistic effects on nicotinic 
substrates, then the increase in the back-lever response rate in the nicotine study could be 
a result of the animal experiencing extinction on the active lever.  For example, if 
bupropion was acting as a nicotinic antagonist and decreasing the reinforcing efficacy of 
nicotine by blocking the release of DA in the NA, then the increase in the overall 
response rate on the active lever could be viewed as an extinction burst.  At the present 
time, it is unclear why bupropion resulted in an increase in the back lever response rate 
specific only to nicotine self-administration.  Further research in this area may aid in a 
better understanding of this effect of the drug. 
An important aspect to consider when testing potential pharmacotherapeutics for 
nicotine addiction is the effect that the drug may have on conditioned reinforcers that 
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become paired with the delivery of the drug.  Conditioned reinforcers have been found to 
be important in the maintenance and acquisition of nicotine self-administration both in 
the animal (Caggiula, Donny, Chaudhri et al., 2002; Caggiula et al., 2001; Caggiula, 
Donny, White et al., 2002) and human (Rose et al., 1999; Westman, Behm, & Rose, 
1996) self-administration paradigms.  The increase in timeout responding seen in all three 
studies may be the drug affecting the conditioned reinforcers (i.e. lights, tones, and sound 
of the drug pump or the pellet dispenser) that were paired with the nicotine infusion or 
the food pellet.  It has been shown that stimulants and more specifically monoamine 
reuptake inhibitors increase responding maintained through conditioned reinforcement 
(Robbins, Watson, Gaskin, & Ennis, 1983).  The increase in the number of timeout 
responses could be a result of bupropion’s ability to block the reuptake of DA or even 
NE.  It has been shown that cues can reinstate nicotine responding (Caggiula et al., 2001) 
and that dopaminergic mechanisms are involved in nicotine abuse (Dani & Heinemann, 
1996) and relapse of abused drugs (Spealman, Barrett-Larimore, Rowlett, Platt, & 
Khroyan, 1999).  Perhaps bupropion’s effects on conditioned cues through dopaminergic 
activity may play a role in its clinical effectiveness in smoking cessation.  
Results from the current study indicate that bupropion is not having reinforcer-
specific effects on nicotine self-administration. Rather, the drug is having qualitatively 
similar effects on behavior regardless of the maintaining event when rates of responding 
are somewhat comparable.  Results from the food-satiated study indicate that bupropion 
is still increasing behavior maintained by food reinforcement, but the effect is not as 
pronounced.  When the rates of behavior are extremely different, the drug resulted in 
qualitatively different effects.  The qualitatively different effects can be seen when 
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comparing the increasing effects of bupropion on nicotine self-administration to the 
decreasing effects of the drug on food-maintained responding under food deprivation 
conditions.  
The current studies indicate that bupropion is affecting smoking cessation through 
some mechanism other than the nicotine in the cigarette.  Perhaps the effectiveness of 
bupropion as a smoking cessation adjunct could be improved by taking into consideration 
the drug’s rate-dependent effects.  It may be important to consider the number of 
cigarettes the individual smokes each day when prescribing bupropion as a 
pharmacological aid in smoking cessation.  The two clinical trials (Hurt et al., 1997; 
Jorenby et al., 1999) kept the number of cigarettes smoked per day relatively constant 
across all groups receiving placebo and doses of bupropion so it is impossible to 
determine what effect level of smoking had on the drug’s ability to increase smoking 
abstinence.  The individual’s rate of smoking may determine whether or not bupropion 
will benefit or hinder their attempts at smoking cessation.   
 Despite the fact that bupropion doesn’t appear to be acting specifically on 
nicotinic substrates, its clinical efficacy as a pharmaceutical aid in smoking cessation 
cannot be ignored.  Future studies in both the human and animal self-administration 
paradigms may elucidate how bupropion is affecting smoking cessation.  Although it is 
extremely beneficial for a nicotinic pharmacotherapeutics to act on the specific neural 
nicotinic substrates, it may be helpful to test potential pharmacotherapeutic’s effects on 
the conditioned cues associated with nicotine delivery. With continued use of the current 
procedures and with the addition of a procedure to test drug’s effects on conditioned 
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cues, perhaps a more effective pharmacotherapeutic can be found that will assist in 
nicotine addiction.   
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